Medtronic (MDT) announced FDA clearance for its new InPen app featuring missed meal dose detection, paving the way for the launch of its Smart MDI system with the Simplera continuous glucose monitor, or CGM. The company’s Smart MDI system combines its InPen smart insulin pen with its newest Simplera(TM) CGM – the company’s first disposable, all-in-one CGM that’s half the size of previous Medtronic CGMs. With this clearance, the system will be the first in the market to recommend corrections for missed or inaccurate insulin doses, providing real-time, personalized insights for individuals on multiple daily injection therapy. Medtronic will initiate a limited market release beginning with existing standalone CGM and InPen customers followed by a broad commercial launch.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MDT:
- Medtronic price target raised to $97 from $96 at Bernstein
- Medtronic price target lowered to $93 from $96 at Baird
- Medtronic price target lowered to $98 from $106 at Wells Fargo
- Medtronic Reports Strong Q2 2025 Results, Raises Guidance
- Trump Trade: President-elect seeks to kill Biden fuel-efficiency rules
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
